FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma.
OBJECTIVE
We performed a prospective cohort study in a homogeneous patient group with proven glioblastoma who received uniform therapy to determine the prognostic value and clinical correlates of [18F]fluorodeoxyglucose (FDG) PET at different stages of the disease.


METHODS
Fifteen newly diagnosed patients with glioblastoma, aged 52 +/- 9 years and with Karnofsky performance score (KPS) of at least 50, were treated with surgical resection, chemotherapy (nimustine), and radiotherapy. They were followed prospectively for 2 years. Clinical data (e.g., tumor progression, performance status, and survival) were recorded and glucose metabolism was measured with PET and FDG before and during radiochemotherapy.


RESULTS
Median survival of all patients was 13 months and four patients were alive 24 months after surgery. All tumors were hypermetabolic compared with normal white matter. A metabolic index was calculated as the ratio of maximum residual tumor metabolism to contralateral normal brain metabolism. It was of prognostic value for patient survival and tumor recurrence already in the first postoperative and all following PET studies and was correlated with the KPS. Reduction of contralateral brain metabolism was more closely related to prognosis than the tumor metabolism proper.


CONCLUSIONS
These results underscore the prognostic relevance of metabolically active residual tumor tissue after surgical resection.
Max-Planck-Institut für neurologische Forschung und Neurologische Universitätsklinik, Köln, Germany.
T
T
Hölzer
K
K
Herholz
J
J
Jeske
W D
WD
Heiss
D000293:Adolescent; D000328:Adult; D000368:Aged; D001921:Brain / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005910:Glioma / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D014055:Tomography, Emission-Computed
D015376:Nimustine; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose